NeuroSense Therapeutics (NASDAQ:NRSN) Stock Dropped to Hold by Roth Capital

Roth Capital cut shares of NeuroSense Therapeutics (NASDAQ:NRSN) from a strong-buy rating to a hold rating in a research note released on Monday morning,Zacks reports.

Several other brokerages also recently issued reports on NRSN. Weiss Ratings downgraded NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 30th. HC Wainwright assumed coverage on shares of NeuroSense Therapeutics in a report on Thursday, September 3rd. They set a “buy” rating on the stock. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, NeuroSense Therapeutics has a consensus rating of “Hold” and an average target price of $170.00.

NeuroSense Therapeutics Trading Up 0.3%

NRSN stock opened at $3.49 on Monday. NeuroSense Therapeutics has a 52 week low of $3.28 and a 52 week high of $26.64. The company has a market cap of $6.63 million, a P/E ratio of -0.32 and a beta of 1.66. The company’s 50-day moving average price is $7.15 and its 200 day moving average price is $12.11.

Institutional Investors Weigh In On NeuroSense Therapeutics

A hedge fund recently bought a new stake in NeuroSense Therapeutics stock. Yorkville Advisors Global LP purchased a new stake in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 78,000 shares of the company’s stock, valued at approximately $56,160. Yorkville Advisors Global LP owned 0.21% of NeuroSense Therapeutics at the end of the most recent quarter. 1.04% of the stock is currently owned by institutional investors.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company’s research is centered on therapeutic approaches intended to address multiple disease mechanisms, including neuroinflammation, abnormal RNA regulation and other biological processes associated with the progression of neurological disorders.

Its leading product candidate is PrimeC, an oral combination formulation of ciprofloxacin and celecoxib being developed primarily for amyotrophic lateral sclerosis (ALS).